文章核心观点 - 尽管大盘持续走高,但也显示出日益增加的波动性和不确定性[1] - 防御性行业和股票创出新高,而之前的领头羊股票则徘徊在低位[1][2] - 投资者应关注防御性股票,如医疗、公用事业和房地产等,这些行业在过去6周表现出色[3] 行业和公司总结 医疗行业 - 公司DaVita是美国最大的透析服务提供商之一,拥有37%的市场份额[4] - DaVita的盈利预测不断上调,预计未来3-5年内年均盈利增长17.5%[5][34] - 目前DaVita股价估值处于折价水平,PEG仅为0.9[60] 烟草行业 - 菲利普莫里斯(Philip Morris)正在向无烟产品转型,为投资者带来新的机会[61] - 该公司股价近期出现强劲突破,并获得Zacks第2级(买入)评级[61] - 公司派息率较高,过去15年派息年复合增长率达8.4%[62] 房地产行业 - 斯塔伍德房地产信托(Starwood Property Trust)是美国最大的商业抵押贷款REIT之一[63][64] - 该公司在商业贷款、基础设施贷款和房地产投资等领域均有涉足,实现了多元化[64] - 公司目前股价处于突破边缘,并提供9.4%的高股息收益[65]

Wall Street has been maintaining its northbound journey in the second half of 2024 after an impressive first half. U.S. stock markets’ rally, which started at the beginning of 2023 is showing no signs of declining barring some minor fluctuations. The rally is likely to gather pace over the remaining months this year as an interest rate cut in September is now almost certain.Under this circumstance, it should be prudent for investors to put money in those stocks with strong momentum. Here we are recommending ...

Have you been paying attention to shares of DaVita HealthCare (DVA) ? Shares have been on the move with the stock up 6.6% over the past month. The stock hit a new 52-week high of $151.05 in the previous session. DaVita HealthCare has gained 42.1% since the start of the year compared to the 8.6% move for the Zacks Medical sector and the 11.4% return for the Zacks Medical - Outpatient and Home Healthcare industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surpris ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

DENVER, Aug. 8, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) ("DaVita") announced today the pricing of its previously announced private offering (the "offering") of $1.0 billion aggregate principal amount of its 6.875% senior notes due 2032 (the "2032 notes"). The 2032 notes were priced at 100.000% of their face amount to yield a 6.875% coupon. The offering is expected to close on August 13, 2024, subject to satisfaction of customary closing conditions.DaVita intends to use the net proceeds from the offerin ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true valuation metr ...

DENVER, Aug. 8, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) ("DaVita") announced today that it has commenced a private offering (the "offering") of $1.0 billion aggregate principal amount of its senior notes due 2032 (the "2032 notes"), subject to market and other conditions.DaVita intends to use the net proceeds from the offering to (i) repay a portion of its outstanding Term Loan B-1 facility borrowings maturing in 2026 and a portion of its outstanding revolving credit facility borrowings, in each case, ...

DaVita Inc. (DVA) delivered adjusted earnings per share (EPS) of $2.59 in the second quarter of 2024, up 24.5% year over year. The figure topped the Zacks Consensus Estimate by 4.9%.GAAP EPS for the quarter was $2.50, reflecting a surge of 30.9% year over year.Revenues in DetailRevenues of $3.19 billion in the second quarter increased 6.2% year over year. The figure surpassed the Zacks Consensus Estimate by 0.7%.Per management, the revenue uptick primarily resulted from a seasonal improvement from patients ...

财务数据和关键指标变化 - 第二季度调整后营业收入为5.06亿美元,调整后每股收益为2.59美元,自由现金流为6.54亿美元 [29] - 调整后营业收入增长主要来自于收款能力的持续改善和合同谈判带来的适度涨价 [17][20][21] - 调整后营业收入指引从之前的18.75亿美元至19.75亿美元上调至19.1亿美元至20.1亿美元,中值增加3500万美元 [26][42][43] 各条业务线数据和关键指标变化 - 美国透析业务治疗量环比增长1.1%,同比增长0.5个百分点 [33] - 治疗量增长低于预期,主要受到5月和6月严重天气事件导致的误治率上升和新增患者增长低于预期的影响 [34][35] - 全年治疗量增长预计在0.5%至1%之间 [35] 各个市场数据和关键指标变化 - 国际业务营业利润保持平稳,公司已完成在厄瓜多尔和智利的收购,预计第三季度完成在哥伦比亚的收购,年底前完成在巴西的收购 [37][38] 公司战略和发展方向及行业竞争 - 公司继续加强临床能力,优化收入、运营和成本结构 [8] - 公司正在与医疗保险公司进行谈判,努力弥补高通胀带来的影响 [21][104] - 公司正在评估增加债务以维持3-3.5倍的目标杠杆比率,为未来增长提供资金支持 [92][93][94][95][96] 管理层对经营环境和未来前景的评论 - 管理层认为目前的收益能力是可持续的,但对2025年的收益增长预期相对谨慎,不会达到2024年的水平 [109][110] - 管理层表示目前的死亡率上升没有结构性原因,预计未来会恢复正常水平,但具体时间难以预测 [99][100][101] 其他重要信息 - 公司将不再将中心关闭成本从调整后业绩中剔除,2024年预计约6000万美元,2025年预计2000万至3000万美元 [30][31][32] - 公司正在与医学院合作开发肾脏护理专业课程,并建立实习和住院项目,以应对护理人员短缺 [12][13][14] 问答环节重要的提问和回答 问题1 **Pito Chickering 提问** 对于2024年下半年治疗量增长预期较高的原因 [46][47][48][49] **Javier Rodriguez 回答** 主要是由于2024年下半年多一个工作日,以及对新增患者增长和误治率改善的谨慎预期 [47][48][49] 问题2 **Justin Lake 提问** 治疗量下降50个基点对营业利润的影响 [54][55] **Javier Rodriguez 回答** 大约影响2000万美元 [54][55] 问题3 **AJ Rice 提问** 为什么死亡率持续高于预期 [67][68][69][70][71] **Joel Ackerman 回答** 公司尚未找到死亡率上升的明确原因,正在与医生社区进行沟通,但暂时无法确定何时会恢复正常水平 [68][69][70][71]

DaVita HealthCare (DVA) came out with quarterly earnings of $2.59 per share, beating the Zacks Consensus Estimate of $2.47 per share. This compares to earnings of $2.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.86%. A quarter ago, it was expected that this kidney dialysis provider would post earnings of $1.96 per share when it actually produced earnings of $2.38, delivering a surprise of 21.43%.Over the last four quart ...